292 related articles for article (PubMed ID: 17927863)
1. [Expression and clinical significance of beta-catenin in multiple myeloma].
Li J; Zhang DB; Luo SK; Zhao Y; Huang BH; Gu JL
Ai Zheng; 2007 Sep; 26(9):1010-4. PubMed ID: 17927863
[TBL] [Abstract][Full Text] [Related]
2. [Expression and clinical significance of vascular endothelial growth factor and its receptors in multiple myeloma].
Liu JR; Luo SK; Li J; Su C
Ai Zheng; 2007 Jun; 26(6):652-6. PubMed ID: 17562275
[TBL] [Abstract][Full Text] [Related]
3. [Preliminary report of fludarabine, mitoxantrone and dexamethasone in treating refractory or relapsed multiple myeloma].
Luo SK; Li J; Hong WD; Zhao Y; Tong XZ
Ai Zheng; 2005 Dec; 24(12):1518-21. PubMed ID: 16351805
[TBL] [Abstract][Full Text] [Related]
4. [The expression of beta-catenin and its significance in leukemia cells].
Mai YJ; Qiu LG; Li ZJ; Yu Z; Li CH; Wang YF; Wang GR; Li Q
Zhonghua Xue Ye Xue Za Zhi; 2007 Aug; 28(8):541-4. PubMed ID: 18078131
[TBL] [Abstract][Full Text] [Related]
5. Molecular and biochemical testing in stage III melanoma: multimarker reverse transcriptase-polymerase chain reaction assay of lymph fluid after lymph node dissection and preoperative serum lactate dehydrogenase level.
Nowecki ZI; Rutkowski P; Kulik J; Siedlecki JA; Ruka W
Br J Dermatol; 2008 Sep; 159(3):597-605. PubMed ID: 18616789
[TBL] [Abstract][Full Text] [Related]
6. [Prognostic significance of beta-2-microglobulin in multiple myeloma].
Podol'tseva EI; Morozova EV; Almazov VA
Vopr Onkol; 1996; 42(4):32-5. PubMed ID: 8928455
[TBL] [Abstract][Full Text] [Related]
7. Expression of the lung resistance protein predicts poor outcome in patients with multiple myeloma.
Filipits M; Drach J; Pohl G; Schuster J; Stranzl T; Ackermann J; Königsberg R; Kaufmann H; Gisslinger H; Huber H; Ludwig H; Pirker R
Clin Cancer Res; 1999 Sep; 5(9):2426-30. PubMed ID: 10499614
[TBL] [Abstract][Full Text] [Related]
8. [Study on the relationship of beta-catenin level and sensitivity to Bortezomib of myeloma cell lines].
Zhou LL; Fu WJ; Yuan ZG; Wang DX; Hou J
Zhonghua Xue Ye Xue Za Zhi; 2008 Apr; 29(4):234-7. PubMed ID: 18843976
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of telomerase activity in multiple myeloma.
Shiratsuchi M; Muta K; Abe Y; Motomura S; Taguchi F; Takatsuki H; Uike N; Umemura T; Nawata H; Nishimura J
Cancer; 2002 Apr; 94(8):2232-8. PubMed ID: 12001122
[TBL] [Abstract][Full Text] [Related]
10. Time to first disease progression, but not beta2-microglobulin, predicts outcome in myeloma patients who receive thalidomide as salvage therapy.
Palumbo A; Bringhen S; Falco P; Cavallo F; Ambrosini MT; Avonto I; Gay F; Caravita T; Bruno B; Boccadoro M
Cancer; 2007 Aug; 110(4):824-9. PubMed ID: 17594696
[TBL] [Abstract][Full Text] [Related]
11. [Analysis of the international staging system of multiple myeloma and its comparison with the DS and IFM staging system in 122 Chinese patients].
Deng SH; Xu Y; Mai YJ; Wang YF; Zhao YZ; Zou DH; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2008 Apr; 29(4):217-21. PubMed ID: 18843972
[TBL] [Abstract][Full Text] [Related]
12. High serum level of endostatin in multiple myeloma at diagnosis but not in the plateau phase after treatment.
Urbańska-Ryś H; Robak T
Mediators Inflamm; 2003 Aug; 12(4):229-35. PubMed ID: 14514474
[TBL] [Abstract][Full Text] [Related]
13. Serum level of interleukin-16 in multiple myeloma patients and its relationship to disease activity.
Alexandrakis MG; Passam FH; Kyriakou DS; Christophoridou AV; Perisinakis K; Hatzivasili A; Foudoulakis A; Castanas E
Am J Hematol; 2004 Feb; 75(2):101-6. PubMed ID: 14755377
[TBL] [Abstract][Full Text] [Related]
14. [Prognostic analysis and assessment on the clinical staging systems of multiple myeloma--a report of 206 cases].
Tao ZF; Fu WJ; Chen YB; Yuan ZG; Wang DX; Hou J
Ai Zheng; 2006 Apr; 25(4):461-4. PubMed ID: 16613681
[TBL] [Abstract][Full Text] [Related]
15. Beta-2-microglobulin level predicts outcome following autologous hematopoietic stem cell transplantation in patients with multiple myeloma.
Stella-Holowiecka B; Czerw T; Holowiecka-Goral A; Giebel S; Wojnar J; Holowiecki J
Transplant Proc; 2007 Nov; 39(9):2893-7. PubMed ID: 18022010
[TBL] [Abstract][Full Text] [Related]
16. [Expression and clinical significance of survivin in bone marrow cells of multiple myeloma patients].
Li J; Zhao Y; Zhang DB; Huang BH
Ai Zheng; 2005 Dec; 24(12):1522-6. PubMed ID: 16351806
[TBL] [Abstract][Full Text] [Related]
17. Relation among p130Cas, E-cadherin and beta-catenin expression, clinicopathologic significance and prognosis in human hepatocellular carcinoma.
Guo C; Liu QG; Yang W; Zhang ZL; Yao YM
Hepatobiliary Pancreat Dis Int; 2008 Oct; 7(5):490-6. PubMed ID: 18842495
[TBL] [Abstract][Full Text] [Related]
18. beta-catenin small interfering RNA successfully suppressed progression of multiple myeloma in a mouse model.
Ashihara E; Kawata E; Nakagawa Y; Shimazaski C; Kuroda J; Taniguchi K; Uchiyama H; Tanaka R; Yokota A; Takeuchi M; Kamitsuji Y; Inaba T; Taniwaki M; Kimura S; Maekawa T
Clin Cancer Res; 2009 Apr; 15(8):2731-8. PubMed ID: 19351774
[TBL] [Abstract][Full Text] [Related]
19. Arsenic trioxide and 2-methoxyestradiol reduce beta-catenin accumulation after proteasome inhibition and enhance the sensitivity of myeloma cells to Bortezomib.
Zhou L; Hou J; Fu W; Wang D; Yuan Z; Jiang H
Leuk Res; 2008 Nov; 32(11):1674-83. PubMed ID: 18485479
[TBL] [Abstract][Full Text] [Related]
20. Correlation of expression levels of BLyS and its receptors with multiple myeloma.
Ju S; Wang Y; Ni H; Wang X; Jiang P; Kong X; Zhong R
Clin Biochem; 2009 Mar; 42(4-5):387-99. PubMed ID: 19028483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
